VATS lobectomy
ProcedurePatients who received lobectomy by video-assisted thoracoscopic surgery
Completed
NCT Number: NCT03613467
Is Video-assisted Thoracoscopic Lobectomy a Clinical Alternative for Surgically Resectable Pathologic N2 NSCLC Patients
The study was designed to compare the safety and effectiveness of vedio-assisted thoracoscopic lobectomy with open lobectomy for patients with surgically resectable pathologic N2 non-small cell lung cancer
Completed
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
China PLA General Hospital, Beijing, Beijing Municipality, China
Loading trial locations.
About this study
The is a multi-center retrospective study. Patients with pathologic N2 NSCLC who underwent VATS or open lobectomy between 2014 and 2017 were included into this study. Clinical data on patient demographic, clinical characteristics, treatment and clinical outcomes will be collected to evaluate the safety and effectiveness of video-assisted thoracoscopic lobectomy for pathologic N2 NSCLC.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients with age > 18 years old;
- Patients with pathologically diagnosed non-small cell lung cancer;
- Patients underwent lobectomy by either VATS or thoracotomy between 2014 and 2017;
- Patients who received lymphadenectomy for all accessible lymph nodes;
- Patients with N2 lymph nodes (+) after surgeries;
Exclusion criteria
- Patients with second primary tumors or multiple primary tumors;
- Patients who received chest surgeries before hospitalization;
- Patients with superior pulmonary sulcus tumor
Treatment and study plan
Thoracotomy lobectomy
ProcedurePatients who received lobectomy by thoracotomy
Primary outcomes
-
Overall survival
Time frame: 2014-2018
Overall survival
Secondary outcomes
-
Duration of hospital stay [Perioperative outcomes]
Time frame: 2014-2017
Duration of hospital stay [Perioperative outcomes]
-
Postoperative 30 and 90 days [Perioperative outcomes]
Time frame: 2014-2017
Postoperative 30 and 90 days [Perioperative outcomes]
-
Drainage time [Perioperative outcomes]
Time frame: 2014-2017
Drainage time [Perioperative outcomes]
-
Intraoperative blood loss [Perioperative outcomes]
Time frame: 2014-2017
Intraoperative blood loss [Perioperative outcomes]
-
Postoperative complications [Perioperative outcomes]
Time frame: 2014-2017
Postoperative complications [Perioperative outcomes]
Other outcomes
-
Overall survivals in the subgroups stratified by T staging
Time frame: 2014-2018
Overall survivals in the subgroups stratified by T staging
-
Overall survivals in the subgroups stratified by neoadjuvant therapy
Time frame: 2014-2018
Overall survivals in the subgroups stratified by neoadjuvant therapy
-
Overall survivals in the subgroups stratified by number of lymph node station involved
Time frame: 2014-2018
Overall survivals in the subgroups stratified by number of lymph node station involved
-
Impact factors for overall survival
Time frame: 2014-2018
Impact factors for overall survival
-
Impact factors for postoperative mortality within 30/90 days
Time frame: 2014-2017
Impact factors for postoperative mortality within 30/90 days
-
Propensity score matching analysis of overall survival
Time frame: 2014-2018
Propensity score matching analysis of overall survival
-
Propensity score matching analysis of perioperative outcomes
Time frame: 2014-2018
Propensity score matching analysis of perioperative outcomes
-
Propensity score matching analysis of impact factors for overall survival
Time frame: 2014-2018
Propensity score matching analysis of impact factors for overall survival
-
Propensity score matching analysis of impact factors for postoperative mortality within 30/90 days
Time frame: 2014-2018
Propensity score matching analysis of impact factors for postoperative mortality within 30/90 days
Sponsors and collaborators
Lead sponsor
Tang-Du Hospital
Other
Collaborators
- LinkDoc Technology (Beijing) Co. Ltd.
Registry information
Official study title
Vedio-assisted Thoracoscopic Lobectomy vs Open Lobectomy for Patients With Surgically Resectable Pathologic N2 NSCLC
Important dates
- Study start
- 2018
- Primary completion
- 2018
- Study completion
- 2018
- First posted
- Aug 3, 2018
- Registry last updated
- Aug 9, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Completed
Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
NCT02718066
Adenocarcinoma, Bronchial Neoplasms
Phoenix, Arizona, United States
View Trial Details
Completed
Hybrid Dose-fraction Radiotherapy for Metastatic Non-small Cell Lung Cancer
NCT05348668
Bronchial Neoplasms, Carcinoma, Bronchogenic
Hefei, Anhui, China
View Trial Details
Completed
Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer
NCT04702009
Advanced Lung Carcinoma, Bronchial Neoplasms
Shanghai, Shanghai Municipality, China
View Trial Details
Completed
The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer
NCT06477055
Bronchial Neoplasms, Carcinoma, Bronchogenic
Changsha, Hunan, China
View Trial Details